KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux, Claudia Baldus, Massimo Bernardi, Céline Berthon, Monica Bocchia, Caroline Bonmati, Erika Borlenghi, Martin Bornhäuser, Diana Carp, Sylvain Chantepie, Enrico Crea, Mariadomenica Divona, Hartmut Döhner, Gerhard Ehninger, Jordi Esteve Reyner, Jamilé Frayfer, Ana Garrido Diaz, Cristina Gil, Luca Guarnera, Anna Franziska Hamm, Maël Heiblig, Daniela Heidenreich, Alwin Johannes Krämer, Marie-Pierre Ledoux, Monia Lunghi, Valentina Mancini, Klaus Metzeler, Maria Cristina Miggiano, Carsten Müller-Tidow, Pierre Peterlin, Alfonso Piciocchi, Kathrin Rieger, Christoph Röllig, Giovanni Rossi, Miguel A Sanz, Hubert Serve, Maaike Söhne, Karsten Spiekermann, Emmanuelle Tavernier-Tardy, Christian Thiede, Susana Vives Polo, Wichard Vogel, Patrizia Zappasodi, Pauline Ziller-Walter, Maria Teresa Voso, SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups

J Clin Oncol 43(29) 3160-3169

PMID40825164
PMCID-
DOI10.1200/JCO-25-00535
发表日期2025-08-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140). METHODS: Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m2 twice daily and idarubicin 12 mg/m2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS: As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients (P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events (P < .01). CONCLUSION: The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。